[A18-26] Abiraterone acetate (prostate cancer) - Addendum to Commission A17-64

Last updated 07.06.2018

Project no.:
A18-26

Commission:
Commission awarded on 25.04.2018 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)

Result of dossier assessment:

Changes both in positive and in negative effects; as a conclusion still proof of a considerable added benefit

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2018-06-07 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form